Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.72 |
| ▸ | LTA4H | P09960 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | BAX | Q07812 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21133961 | 0.98 | SRD5A2 (0.75) | SRD5A2LTA4HTSHRNR1H2BAX | |
| SCHEMBL28016900 | 0.88 | SRD5A2 (0.59) | SRD5A2LTA4HMAOANPY5R | |
| SCHEMBL11605458 | 0.86 | SRD5A2 (0.62) | SRD5A2LTA4HTSHRNR1H2BAX | |
| SCHEMBL477413 | 0.85 | PTGS1 (0.59) | SRD5A2LTA4HTSHRNR1H2BAX | |
| SCHEMBL13886755 | 0.85 | PTGS1 (0.59) | SRD5A2LTA4HTSHRNR1H2BAX | |
| SCHEMBL11605250 | 0.84 | SMN1; SMN2 (0.74) | SRD5A2TSHRSMN1; SMN2 | |
| SCHEMBL8895993 | 0.83 | PTGS1 (0.61) | SRD5A2LTA4HTSHRNR1H2BAX | |
| SCHEMBL8671295 | 0.83 | SMN1; SMN2 (0.58) | SRD5A2TSHRCA1CA2SMN1; SMN2 | |
| SCHEMBL13326419 | 0.81 | LTA4H (0.60) | SRD5A2LTA4HTSHRNR1H2BAX | |
| SCHEMBL25864476 | 0.81 | LTA4H (0.60) | SRD5A2LTA4HTSHRNR1H2BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023057548-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-04-13 | — | — | WO | disclosed |
| US-8563786-B2 | Method for producing optically active alcohol | MITSUI CHEMICALS, INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-12 | — | — | US | disclosed |
| EP-2412694-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Mitsui Chemicals, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355079-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321065-B2 | Thyronamine derivatives and analogs and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1625111-A4 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060035980-A1 | Thyronamine derivatives and analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-16 | — | — | US | disclosed |
| EP-1625111-A2 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050096485-A1 | Thyronamine derivatives and analogs and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-05-05 | — | — | US | disclosed |
| WO-2004093800-A2 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105347-A1 | THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF | TPO, TSHR, THRB | SRD5A2 34/4885LTA4H 1070/4885TSHR 2/4885 |
| US-20060035980-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | SRD5A2 37/4885LTA4H 1059/4885TSHR 2/4885 |
| US-20050096485-A1 | Thyronamine derivatives and analogs and methods of use thereof | TPO, TSHR, THRB | SRD5A2 34/4885LTA4H 1070/4885TSHR 2/4885 |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1A, ADH1C, FHIT | SRD5A2 436/4885LTA4H 2533/4885TSHR 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.